aibioTheriva Biologics cuts 32% of workforce, expects cash runway into second quarter of 2026
Tickers TOVX
Theriva says cutting about seven employees, or 32% of its global workforce, and other cost cuts extend its cash runway into the second quarter of 2026. Its 2024 annual report carried a going-concern warning, and the company reported $11.6 million of cash and equivalents at December 31, 2024.
Key facts
- Company
- Theriva Biologics, Inc. (AMEX: TOVX)
- News type
- Distress
- Primary source
- Theriva Biologics, Inc. Form 8-K filed October 2, 2025 (SEC EDGAR)
Theriva Biologics, Inc. said it cut about 32% of its global workforce under a restructuring plan and expects the savings, together with other cost reductions, to extend its cash runway into the second quarter of 2026. The company disclosed the reduction in a Form 8-K filed October 2, 2025 under Item 2.05, which covers costs of exit or disposal activities such as layoffs. The company's stock is listed on the NYSE American.
What the filing says
The board approved the plan on September 28, 2025. The company says the plan aims to focus its attention on business development and licensing and on its upcoming meetings with the U.S. Food and Drug Administration and the European Medicines Agency. Those meetings concern planned clinical trials in metastatic pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma.
On September 30, 2025, the company carried out the reduction of approximately seven employees, or 32% of its current global workforce. Theriva says the goal is to direct resources toward business development and licensing and toward its lead candidate, VCN-01, in PDAC and retinoblastoma. The company says it believes this "will represent its best opportunity for success."
Costs, savings and the runway claim
Theriva expects to substantially complete the reduction immediately. It estimates total charges of approximately $520,000, all to be incurred in the fourth quarter of 2025, mainly as cash severance and benefits paid over three months. The plan is expected to save approximately $2.0 million a year in compensation and benefits. Together with further operating cost reductions, the company expects that to extend its cash runway into the second quarter of 2026.
The filing hedges those figures. The estimates of charges and their timing rest on assumptions, including local law requirements in various jurisdictions, and actual amounts may differ materially. The company may also incur charges not currently contemplated. The risks it names include whether it will successfully advance its VCN-01 trials and whether the annual cost reductions will be achieved.
The money behind the runway
The 2024 annual report, filed March 6, 2025, says operating activities used net cash of approximately $16.9 million in 2024. It reports cash and cash equivalents of $11.6 million at December 31, 2024. The report also says the consolidated financial statements were prepared assuming the company will continue as a going concern for the next twelve months. Its auditor's report carries an explanatory paragraph on that point, citing recurring losses from operations and a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. The report said the company expected its cash to fund operations into the third quarter of 2025, but not for twelve months from the filing date.
The company says it will need to raise additional capital, and that its ability to continue as a going concern depends on obtaining equity or debt financing, reaching further operating efficiencies and reducing expenditures. The 8-K does not give a current cash balance or say how the runway moved from the third quarter of 2025 to the second quarter of 2026.
The lead program
The filing describes VCN-01 as a clinical-stage oncolytic human adenovirus, modified for tumor-selective replication and to express the enzyme PH20, a hyaluronidase. It has been tested in a Phase 2b study in pancreatic cancer called VIRAGE, and it has recently been used to treat patients in a Phase 1 study for retinoblastoma.
Before its 2022 acquisition of the company that holds the adenovirus platform, Theriva focused on gastrointestinal diseases. The 2024 annual report says it is exploring value-creation options for its earlier assets SYN-004 (ribaxamase) and SYN-020, including out-licensing or partnering them.
Who signed
Steven A. Shallcross, chief executive officer and chief financial officer, signed the October 2, 2025 Form 8-K. The 2024 annual report lists him as chief executive officer, chief financial officer and director, and names Jeffrey J. Kraws as chairman.